Business · 17/04/2013
FDA Releases Guidance on Preventing Cross-Contamination of Non-Penicillin Beta-Lactam Drugs
The FDA has announced the availability of a guidance document outlining the importance of preventing cross-contamination of non-penicillin beta-lactam drugs, which can pose health risks due to cross-reactivity, and recommends the use of separate facilities for their manufacture.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →